Control of whole body energy homeostasis by microRNA regulation
The disclosure provides a method of regulating fatty acid or glucose metabolism in a cell by contacting the cell with a modulator of miR-208a and/or miR-208b activity or expression. The disclosure also provides a method of treating or preventing a metabolic disorder, such as obesity, diabetes, or metabolic syndrome, in a subject by administering to the subject an inhibitor of miR-208a and/or miR-208b activity or expression. Also provided is a method of enhancing or improving mitochondrial function and/or redox-homeostasis in a subject by administering to the subject an inhibitor of miR-208a and/or miR-208b activity or expression.
1. A method of treating obesity, hypercholesterolemia, type 2 diabetes, hepatic steatosis, hyperlipidemia, insulin resistance, a glycogen storage disease, or aberrant glucose uptake and/or utilization in a subject in need thereof comprising administering to the subject an inhibitor of miR-208a and/or miR-208b, wherein the inhibitor is an antisense oligonucleotide, wherein the antisense oligonucleotide comprises a sequence that is at least partially complementary to a mature sequence of miR-208a and/or miR-208b, and wherein the expression or activity of miR-208a and/or miR-208b is reduced in the cells of the subject following administration.
2. The method of claim 1 , wherein the antisense oligonucleotide comprises a sequence that is at least partially complementary to SEQ ID NO: 9 or SEQ ID NO: 11.
3. The method of claim 1 , wherein the antisense oligonucleotide comprises at least one sugar and/or backbone modification.
4. The method of claim 3 , wherein the sugar modification is a locked nucleic acid, a 2′-O-alkyl modification, or a 2′-halo modification.
5. The method of claim 4 , wherein the 2′-halo modification is a 2′-fluoro modification.
6. The method of claim 3 , wherein the backbone modification is a phosphorothioate linkage.
7. The method of claim 1 , wherein the antisense oligonucleotide is about 6 to about 22 nucleotides in length.
8. The method of claim 1 , wherein the antisense oligonucleotide has a sequence of SEQ ID NO:3 or SEQ ID NO:4.
9. The method of claim 8 , wherein the antisense oligonucleotide has the structure of Compound 10101 (SEQ ID NO: 13), 10673 (SEQ ID NO: 18), 10674 (SEQ ID NO: 19), 10677 (SEQ ID NO: 20), 10679 (SEQ ID NO: 21), 10707(SEQ ID NO: 26), 10680 (SEQ ID NO: 22), 10681 (SEQ ID NO: 23), or 10683 (SEQ ID NO: 25).
10. The method of claim 1 , wherein the subject is human.
11. The method of claim 1 , wherein the inhibitor is administered to the subject by an intradermal, subcutaneous, intramuscular, intraperitoneal or intravenous route of administration.
12. The method of claim 1 , wherein the antisense oligonucleotide contains at least 9 locked nucleotides.
13. A method of regulating fatty acid or glucose metabolism in a subject in need thereof comprising administering an inhibitor of miR-208a and/or miR-208b expression or activity to the subject, wherein the inhibitor of miR-208a and/or miR-208b is an antisense oligonucleotide comprising a sequence that is at least partially complementary to a mature sequence of miR-208a and/or miR-208b.
14. The method of claim 13 , wherein fatty acid or glucose metabolism is increased in the subject following administration of the inhibitor as compared to a subject not administered the inhibitor.
15. The method of claim 13 , wherein the cell is a cardiomyocyte, a skeletal muscle cell, a preadipocyte, an adipocyte, or a hepatocyte.
16. The method of claim 13 , wherein the cell is in vitro or in vivo.
17. The method of claim 13 , wherein the antisense oligonucleotide contains at least 9 locked nucleotides.
18. A method of enhancing mitochondrial function or redox-homeostasis in a subject in need thereof comprising administering to the subject an antisense oligonucleotide comprising a sequence that is at least partially complementary to a miR-208a or miR-208b sequence, wherein the expression or activity of milt-208a or miR-208b is reduced in the cells of the subject following administration of the antisense oligonucleotide.
19. The method of claim 18 , wherein the antisense oligonucleotide contains at least 9 locked nucleotides.